Wednesday, February 10, 2010, 2:24am EST - Canadian Markets open in 7 hours and 6 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Aradigm Corp. (ARDM.OB)

 On Feb 9: 0.1375 USD  Down 0.0025 (1.79%)  
MORE ON ARDM.OB
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
ARADIGM CORP (OTC BB:ARDM.OB) Delayed quote dataEdit
Last Trade: 0.1375 USD
Trade Time: Feb 9
Change: Down 0.0025 (1.79%)
Prev Close: 0.14
Open: 0.14
Bid: 0.133 x 5000
Ask: 0.14 x 5000
1y Target Est: 2.25
Day's Range: 0.13 - 0.14
52wk Range: 0.40 - 2.00
Volume: 46,890
Avg Vol (3m): 74,340.6
Market Cap: 14.08M
P/E (ttm): N/A
EPS (ttm): -0.194
Div & Yield: N/A (N/A%)
Aradigm Corp. (ARDM.OB)
1d  5d  3m  6m  1y  2y  5y  max 
 Add ARDM.OB to Portfolio   Download Data

HEADLINES
• Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Business Wire (Thu, Feb 4)
• Aradigm to Present at Biotech Showcase 2010 on January 12
Business Wire (Wed, Jan 6)
• Aradigm Lippert/Heilshorn Life Sciences Call scheduled for 12:00 pm ET today
Vcall (Tue, Dec 15)
• Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15
Business Wire (Thu, Dec 10)
• AllPennyStocks.com Announces November 23rd to November 27th U.S. Penny Stocks 2 Watch (LPIH.OB, ARDM.OB)
BayStreet Newswire (Fri, Nov 20)
• Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Br
Business Wire (Mon, Nov 16)
• ARADIGM CORP Financials
EDGAR Online Financials (Fri, Nov 13)
• ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 6)
• ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Aug 7)
• ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Aug 6)
More Headlines for ARDM.OB...
ANALYST
EPS Est (next year) (Dec-09) : -0.14
EPS Est (in 2 years) (Dec-10) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices